The Prospective Studies of Atherosclerosis (Proof-ATHERO) consortium: Design and rationale

Writing committee: Lena Tschiderer[1§], Lisa Seekircher[1§], Gerhard Klingenschmid[1], Raffaele Izzo[2], Damiano Baldassarre[3,4], Bernhard Iglseder[5,6], Laura Calabresi[7], Jing Liu[8], Jackie F. Price[9], Jang-Ho Bae[10,11], Frank P. J. Brouwers[12], Eric de Groot[13], Caroline Schmidt[14], Göran Bergström[15,16], Gülay Aşçi[17], Paolo Gresele[18], Shuhei Okazaki[19], Kostas Kapellas[20], Manuel F. Landecho[21], Naveed Sattar[22], Stefan Agewall[23], Zhi-Yong Zou[24], Christopher D. Byrne[25], Prabath W. B. Nanayakkara[26], Aikaterini Papagianni[27], Miles D. Witham[28], Enrique Bernal[29], Robert Ekart[30], Michiel A. van Agtmael[31], Mario F. Neves[32], Eiichi Sato[33], Marat Ezhov[34], Matthew Walters[35], Michael H. Olsen[36], Radojica Stolić[37], Dorota A. Zozulińska-Ziółkiewicz[38], Markolf Hanefeld[39], Daniel Staub[40], Michiaki Nagai[41], Pythia T. Nieuwkerk[42], Menno V. Huisman[43], Akihiko Kato[44], Hirokazu Honda[45], Grace Parraga[46], Dianna Magliano[47], Rafael Gabriel[48], Tatjana Rundek[49], Mark A. Espeland[50], Stefan Kiechl[1], Johann Willeit[1], Lars Lind[51], Jean Philippe Empana[52], Eva Lonn[53,54], Tomi-Pekka Tuomainen[55], Alberico Catapano[7,56], Kuo-Liong Chien[57], Dirk Sander[58,59], Maryam Kavousi[60], Joline W. J. Beulens[60], Michiel L. Bots[62], Michael J. Sweeting[63,64], Matthias W. Lorenz[65], and Peter Willeit[1,64]* on behalf of the Proof-ATHERO Study Group[‡].

[§]Denotes equal contribution.

[‡]The members of the collaborators committee are listed at end of the paper.

[1]Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; [2]Department of Advanced Biochemical Sciences, Federico II University, Naples, Italy; [3]Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy; [4]Centro Cardiologico Monzino IRCCS, Milan, Italy; [5]Department of Geriatric Medicine, Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft GmbH Christian-Doppler-Klinik, Salzburg, Austria; [6]Department of Geriatric Medicine, Paracelsus Medical University, Salzburg, Austria; [7]Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; [8]Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; [9]Usher Institute, University of Edinburgh, Edinburgh, UK; [10]Heart Center, Konyang University Hospital, Daejeon, Korea; [11]Department of Cardiology, Konyang University College of Medicine, Daejeon, Korea; [12]Department of Cardiology, Haga Teaching Hospital, the Hague, the Netherlands; [13]Imagelabonline & Cardiovascular, Eindhoven and Lunteren, the Netherlands; [14]Wallenberg Laboratory for Cardiovascular Research, University of Gothenburg, Gothenburg, Sweden; [15]Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; [16]Department of Clinical Physiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; [17]Nefroloji Bilim Dalı, Ege Üniversitesi, Bornova-İzmir, Turkey; [18]Division of Internal and Cardiovascular Medicine, Department of Medicine, University of Perugia, Perugia, Italy; [19]Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan; [20]Australian Research Centre for Population Oral Health, University of Adelaide, Adelaide, SA, Australia; [21]Department of Internal Medicine, University Clinic of Navarra, Navarra, Spain; [22]BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; [23]Oslo University Hospital Ullevål and Institute of Clinical Sciences, University of Oslo, Oslo, Norway; [24]Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China; [25]Human Development and Health

Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences, University of Southampton - Southampton General Hospital, Southampton, UK; [26]Department of Clinical Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands; [27]University Department of Nephrology, Hippokration General Hospital, Thessaloniki, Greece; [28]AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle-upon-Tyne Hospitals Trust, Newcastle, UK; [29]Infectious Diseases Unit, Reina Sofia Hospital, Murcia, Spain; [30]Department of Dialysis, University Medical Centre Maribor, Maribor, Slovenia; [31]Department of Internal Medicine, Amsterdam UMC- Location Vumc, Amsterdam, the Netherlands; [32]Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil; [33]Division of Nephrology, Shinmatsudo Central General Hospital, Chiba, Japan; [34]Laboratory of Lipid Disorders, National Medical Research Center of Cardiology, Moscow, Russia; [35]School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK; [36]Department of Internal Medicine, Holbaek Hospital, University of Southern Denmark, Odense, Denmark; [37]Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia; [38]Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland; [39]Center for Clinical Studies, Technical University Dresden, Dresden, Germany; [40]Department of Angiology, University Hospital Basel, Basel, Switzerland; [41]Department of Internal Medicine, General Medicine and Cardiology, Hiroshima City Asa Hospital, Hiroshima, Japan; [42]Department of Medical Psychology, Amsterdam UMC- Location AMC, Amsterdam, the Netherlands; [43]Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; [44]Blood Purification Unit, Hamamatsu University Hospital, Hamamatsu, Japan; [45]Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan; [46]Department of Medical Biophysics, Western University, London, Canada; [47]Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia; [48]National School of Public Health, Instituto de Salud Carlos III, Madrid, Spain; [49]Department of Neurology, University of Miami Miller School of Medicine, Miami, USA; [50]Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA; [51]Department of Medicine, Uppsala University, Uppsala, Sweden; [52]Paris Cardiovascular Research Centre (PARCC), University Paris Descartes, Paris, France; [53]Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; [54]Hamilton General Hospital, Hamilton, Ontario, Canada; [55]Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland; [56]IRCCS Multimedica, Milan, Italy; [57]Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan; [58]Department of Neurology, Benedictus Hospital Tutzing & Feldafing, Feldafing, Germany; [59]Department of Neurology, Technische Universität München, Munich, Germany; [60]Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands; [61]Department of Epidemiology & Biostatistics, Amsterdam UMC- Location Vumc, Amsterdam, the Netherlands; [62]Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; [63]Department of Health Sciences, University of Leicester, Leicester, UK; [64]Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; [65]Department of Neurology, Goethe University, Frankfurt am Main, Germany

Short Title: Design and rationale of the Proof-ATHERO consortium

***Corresponding author:**
Peter Willeit, MD MPhil PhD, Department of Neurology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria, Tel: +43 512 504-83493, Fax: +43 50 504-23852, E-mail: peter.willeit@i-med.ac.at

Abstract

Atherosclerosis – the pathophysiological mechanism shared by most cardiovascular diseases – can be directly or indirectly assessed by a variety of clinical tests including measurement of carotid intima-media thickness, carotid plaque, ankle-brachial index, pulse wave velocity, and coronary artery calcium. The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium (https://clinicalepi.i-med.ac.at/research/proof-athero/) collates de-identified individual-participant data of studies with information on atherosclerosis measures, risk factors for cardiovascular disease, and incidence of cardiovascular diseases. It currently comprises 74 studies that involve 106,846 participants from 25 countries and over 40 cities. 21 studies recruited participants from the general population (n=67,784), 16 from high-risk populations (n=22,677), and 37 as part of clinical trials (n=16,385). Baseline years of contributing studies range from April 1980 to July 2014; the latest follow-up was until June 2019. Mean age at baseline was 59 (standard deviation: 10) years and 50% were female. Over a total of 830,619 person-years of follow-up, 17,270 incident cardiovascular events (including coronary heart disease and stroke) and 13,270 deaths were recorded, corresponding to cumulative incidences of 2.1% and 1.6% per annum. The consortium is coordinated by the Clinical Epidemiology Team at the Medical University of Innsbruck, Austria. Contributing studies undergo a detailed data cleaning and harmonisation procedure before being incorporated in the Proof-ATHERO central database. Statistical analyses are being conducted according to pre-defined analysis plans and use established methods for individual-participant data meta-analysis. Capitalising on its large sample size, the multi-institutional collaborative Proof-ATHERO consortium aims to better characterise, understand, and predict the development of atherosclerosis and its clinical consequences.

Keywords: Prospective studies · Consortium · Individual-participant data · Atherosclerosis · Repeat measurements · Cardiovascular disease

Introduction

Cardiovascular diseases (CVD) are the most common cause of death and disability worldwide. According to recent estimates from the Global Burden of Disease Study, about 18 million people die of CVD in a year, which account for over 30% of all global deaths [1]. The pathophysiological mechanism shared by many CVD is atherosclerosis, a gradual and progressive hardening and narrowing of the arteries over the course of life. Initial atherosclerotic alterations can be found as early as in young adulthood [2, 3] and involve endothelial dysfunction, inflammation, and deposition of fat [4]. Advanced atherosclerotic lesions are characterised by formation of atherosclerotic plaque that can destabilise, rupture or fissure, and can ultimately lead to acute vessel occlusion or formation of a local thrombus with dislocation into distal arteries and thereby clinical sequelae [4].

Clinical and subclinical atherosclerosis can be directly or indirectly assessed using a range of different clinical tests which are simple, safe, and non-invasive, and therefore amenable for use in large-scale studies (**Fig. 1**). One of the imaging techniques for atherosclerosis most frequently used is the assessment of carotid intima-media thickness (cIMT). Using B-mode high-resolution ultrasound, the distance between the intimal and medial layer of the carotid arterial wall is quantified. Spatial resolution of this imaging technique is approximately 50 µm axially and 200 µm laterally. Ultrasound-based cIMT is considered as a marker of the early stage of atherosclerosis. It is related to unfavourable levels of traditional cardiovascular risk factors [5, 6] and has been shown to be in good accordance with "true" cIMT determined in histological studies [7]. Furthermore, increased cIMT has been associated with increased risk of cardiovascular events [8, 9].

Other scalable and commonly available measures to ascertain vessel wall pathology and dysfunction include the carotid plaque [10, 11], ankle-brachial index [12], pulse wave velocity [13], and coronary artery calcium [14–16] (**Fig. 1**). As reviewed recently [17], these measures have several strengths and weaknesses. cIMT, carotid plaque, ABI, and PWV are non-invasive and cost-effective markers, which are therefore relatively easy to implement in large clinical studies. However, disadvantages include measurement error and lack of standardisation in measurement protocols for cIMT, specificity of ABI [12], and the error associated with the measurement of travelled distance for PWV [18]. Coronary artery calcium directly quantifies presence of calcification in coronary arteries [19]. In contrast to the other mentioned markers, coronary artery calcification is assessed with computed tomography, which is more costly and exposes the study participant to radiation, thereby limiting large-scale assessments.

According to the 2019 European Society of Cardiology Guidelines for the diagnosis and management of chronic coronary syndromes, atherosclerotic plaque detection by carotid artery ultrasound, assessment of coronary artery calcium score with computed tomography, and measurement of the ankle-brachial index may be considered as risk modifiers in cardiovascular risk assessment in asymptomatic subjects [19]. Because atherosclerosis typically develops over a long period of time and only causes symptoms at an advanced stage, these measures are important tools in clinical practice to quantify atherosclerosis burden and might help inform treatment decisions.

The Prospective Studies of Atherosclerosis (Proof-ATHERO) consortium is an international consortium that brings together individual-participant data from prospective cohorts with detailed information on atherosclerosis, covariates, and incidence of CVD outcomes. The present report provides a description of broad aims of the Proof-ATHERO consortium and the principal methodology involved in collating, harmonising, and analysing study data.

Design

Objectives

Capitalising on its large sample size and the comprehensive information available, the overarching aims of the Proof-ATHERO consortium are to: (i) better characterise the natural history, communalities, and differences of different atherosclerosis measures; (ii) to provide novel insight into the determinants of atherosclerosis development and progression; and (iii) to investigate clinical consequences of atherosclerosis. In contrast to prior reports in individual studies, the large-scale data of Proof-ATHERO enables the study team to conduct power-demanding analyses, including (i) characterisation of atherosclerosis trajectories over time; (ii) determination of the shapes of associations (e.g. linear vs. curvilinear vs. threshold effects); (iii) study of potential effect modifiers (e.g. age, sex, ~~or~~ medication, or different lifestyle factors such as smoking habit); (iv) direct comparisons of the added predictive value of different atherosclerosis measures over and beyond assessment of conventional risk factors; and (v) reliable evaluation of atherosclerosis measures as surrogate markers for clinically manifest CVD endpoints. Overall, Proof-ATHERO aims to analyse world-wide available data to deliver results based on the highest scientific evidence.

Inclusion criteria

Prospective cohorts are eligible for inclusion in the Proof-ATHERO consortium if they were observational studies or clinical trials that: (i) have assessed one or more atherosclerosis measures (i.e. cIMT, carotid plaque, ankle-brachial index, pulse wave velocity, and coronary artery calcium) repeatedly (i.e. at two or more time points); (ii) have ascertained comprehensive information on CVD risk factors (e.g. lifestyle, blood-based markers, history of disease, and medication intake); and (iii) have recorded incident CVD outcomes using well-defined criteria.

A crucial foundation for the Proof-ATHERO consortium was provided by the PROG-IMT project [20]. This initiative led by Matthias Lorenz at the Goethe University at Frankfurt am Main had collated and analysed individual-participant data on the progression of cIMT and, for instance, yielded milestone publications on the association of cIMT progression with future CVD risk in the general population [8], in people with type-2 diabetes [21], and in people at high cardiovascular risk [22]. When the PROG-IMT project was completed in 2017, a majority of contributing studies (83%) decided to continue the fruitful collaboration as part of the Proof-ATHERO consortium and to jointly investigate scientific questions which go beyond the initial aims of the PROG-IMT project. The commitment by these studies gave a unique head-start to the Proof-ATHERO consortium and enabled efficient data accrual at the beginning of the initiative.

Identification and incorporation of new eligible studies is ongoing and we invite researchers to contact the coordinating centre if they wish to contribute to the Proof-ATHERO consortium.

Atherosclerosis measures

Data have been sought from investigators on carotid ultrasound parameters, ankle-brachial index, pulse wave velocity, and coronary artery calcium at baseline and any subsequent re-examinations during follow-up. Atherosclerosis measures assessed by the individual studies are summarised in **Table 1**. Parameters based on carotid ultrasound are being collected systematically on up to twelve sites (common carotid artery, carotid bifurcation, and internal carotid artery; left and right side; near and far wall) and include cIMT, vessel diameter, presence of plaques (yes *vs.* no), number of plaques, plaque thickness (height in mm), plaque area in a longitudinal view (in mm^2), and plaque morphology according to the Gray-Weale classification [23]. The methodologies which studies used to cIMT and carotid plaque are summarised in **Table S2** and **Table S3**, respectively.

Participant characteristics at the baseline and follow-up surveys

Data on participant characteristics at baseline and follow-up surveys have been sought from investigators on age, sex, ethnicity, socio-economic status, smoking, systolic and diastolic blood pressure, body-mass index, lipid markers (e.g. total cholesterol, high- and low-density lipoprotein cholesterol, triglycerides), markers of inflammation (e.g. C-reactive protein, fibrinogen, leukocyte count), markers of dysglycaemia (e.g. fasting glucose, glycated haemoglobin), use of medication (e.g. antihypertensive, antidiabetic, lipid-lowering medication), and pre-existing diseases (e.g. coronary heart disease, stroke, diabetes, or hypertension). Furthermore, in clinical trials, information on the type of interventions (and dosages, if appropriate) and on adherence to allocated regimens have been collated.

Incident disease outcomes

Data on incident disease outcomes have been collated predominantly on fatal and non-fatal CVD events, including myocardial infarction, angina pectoris, and subtypes of stroke. A detailed description of ascertainment and classification of prevalent and incident CVD is provided in **Table S4**. Studies assessed prevalent CVD at study baseline using self-report only or supplemented by objective criteria. The vast majority of the studies used objective criteria rather than self-report only for assessing incident coronary heart disease (93%) and incident stroke (90%). In addition, information on cause-specific death has been sought. In 15 studies, cause of death was ascertained based on the death certificate; 44 studies supplemented the death certificate with information from additional sources (e.g. medical records, autopsy findings). ~~Studies assessed prevalent CVD at study baseline using self-report only or supplemented by objective criteria. A detailed description of ascertainment and classification of prevalent and incident CVD is provided in **Table S4**.~~

Coordination of the consortium

The Proof-ATHERO consortium is coordinated by the Clinical Epidemiology team at the Medical University of Innsbruck, Austria. An outline of the processes involved in Proof-ATHERO coordination is provided in **Fig. 2**. Standardised data request forms are sent to eligible studies, inviting them to participate in the initiative. Upon receipt of study data, data cleaning and harmonisation are performed by a dedicated data management team using a range of tools for detecting inconsistencies and ambiguities in the data. Any queries arising during this process are clarified through direct correspondence with study investigators. Upon completion of the

data management process, study data are stored in a central database at the coordinating centre. The data management system of the coordinating centre has been implemented in *SAS 9.4*. Proposals for analyses can be submitted by all members of the Proof-ATHERO study group (i.e. all named investigators of studies contributing data to Proof-ATHERO) via the consortium's webpage. Upon receipt, proposals are reviewed by a dedicated Proof-ATHERO steering committee, which then allocates resources at the coordinating centre according to resource availability and scientific priority of the project. For contractual reasons, data are stored and analysed exclusively at the Proof-ATHERO Coordinating and Statistics Centres (Medical University of Innsbruck and University of Cambridge). At each step from development of a statistical analysis plan, to the conduct of statistical analyses, and the creation of a manuscript draft, investigators of contributing studies and expert panels are contacted for feedback and comments, therefore making use of the broad and diverse community of experts in the field involved in the initiative.

General approach to statistical analyses

For each scientific project, statistical analyses will be performed according to a pre-specified analysis plan. Statistical analyses will follow established methods in the analysis of individual-participant data [24–29]. Generally, the multi-level structure of data (e.g. multiple cohorts) will be taken into account by combining study-specific estimates using meta-analytical methods or by using mixed regression models with appropriate specification of random effects. Analyses will also involve assessments of between-studies heterogeneity. More details on specific analytical methods will be provided in publications resulting from each scientific project.

Data protection and ethics considerations

All studies contributing data to Proof-ATHERO have previously reported results and have obtained relevant local ethics approval and participants' consent. The data provided by each study remain entirely the property of the principal investigators of that study and are held in confidence by the Proof-ATHERO coordinating centre. To safeguard the identity of individuals at all stages of the analysis and to ensure compliance with data protection legislation and confidentiality guidelines, study data are transferred to the coordinating centre using encrypted connections. De-identified data are being stored securely in a central database at the coordinating centre, protected by firewalls and accessible only to authorised staff. Participants

and collaborating studies have the right to withdraw from the Proof-ATHERO consortium at any time and without giving reasons.

Characteristics of contributing studies

As of 24 January 2020, a total of 74 studies involving 106,846 participants are part of the Proof-ATHERO consortium. The designs of contributing studies and key study-level characteristics are shown in **Table 2**. In summary, 21 studies recruited participants from the general population, 16 studies were conducted in patient populations with specific pre-existing diseases (e.g. with diabetes), and 37 studies were randomised controlled trials covering a range of different patient populations. The numbers of people enrolled in these three types of studies were 67,784, 22,677, and 16,385, respectively. Baseline years ranged from April 1980 to July 2014; the last follow-up was in June 2019. Mean age at baseline was 59 years (standard deviation: 10); 50% of participants were female. **Fig. 3** demonstrates the geographical location of contributing studies. Study locations were spread across four continents and are based in 25 countries and over 40 cities. The median duration of follow-up (i.e. the time from baseline to first event or end of follow-up) was 6.1 years (interquartile range: 2.7-10.4). Over a total of 830,619 person-years of follow-up, 17,270 incident CVD events and 13,270 deaths were recorded, corresponding to cumulative incidences of 2.1% and 1.6% per annum, respectively. As Proof-ATHERO evolves further, up-to-date information on contributing studies are being made available on the consortium's webpage at https://clinicalepi.i-med.ac.at/research/proof-athero/.

Initial set of hypotheses to be tested

The large sample size and variety of data in Proof-ATHERO will enable us to test several hypotheses that are particularly power-hungry and could therefore not be addressed by previous studies. For instance, it is unclear whether cIMT progression could serve as a surrogate marker for hard cardiovascular outcomes in clinical trials [30–32]. Second, given conflicting results of prior individual studies [33–39], the comparative predictive value of cIMT measurements at different locations of the carotid artery remains to be determined in detail. Third, building on the initial insights of our recent literature-based meta-analysis [40], Proof-ATHERO will characterise in detail the association of cIMT with long-term risk of developing carotid plaque. In general, as a large-scale consortium of patient-level data, the high statistical power and

consistent approach to statistical analysis and outcome definitions of Proof-ATHERO will help to address the aforementioned and other questions with reliably than previously possible.

Strengths and limitations

Proof-ATHERO is a large consortium with a huge amount of data on atherosclerosis applying consistent approaches to data harmonisation and analysis. By inclusion of data from 25 countries and different clinical settings, the generalisability of findings will be of particular value. Our study also has several limitations. First, there were some differences between studies in how they assessed atherosclerosis measures and clinical outcomes. To address this issue, we collect meticulously a variety of study-specific characteristics, enabling us to quantify and better understand the impact of these differences in future analyses. Second, comprehensive data cleaning and harmonisation is a serious, often underestimated challenge. However, we managed to develop a sophisticated data management system that enables to transparently and effectively handle various datasets with different structures provided by the individual studies. Third, the current focus of available data lies on cIMT due to participation of multiple studies previously involved the PROG-IMT consortium [20]. Fourth, there exist several other markers for atherosclerosis, such as the assessment of endothelial function [41] with flow-mediated dilation or peripheral arterial tone, which have not been collected within Proof-ATHERO yet. Since the consortium is designed to continuously collect new data as they become available, coverage of other atherosclerosis markers will be expanded over time.

Conclusion

The Proof-ATHERO consortium is a multi-institutional collaborative project that is coordinated at the Medical University of Innsbruck. The consortium brings together large-scale data from prospective studies in the field of atherosclerosis. Proof-ATHERO combines data on CVD risk factors, repeat assessments of atherosclerosis, and clinical outcomes with cutting-edge data management and analytical tools. ~~By inclusion of data from 25 countries and different clinical settings, the generalisability of findings will be of particular value.~~ Building on these strengths, Proof-ATHERO will help to better characterise, understand, and predict the development of atherosclerosis and its clinical consequences.

Acknowledgement

This manuscript was prepared using data of the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study (CHS), the Jackson Heart Study (JHS), and the Multi-Ethnic Study of Atherosclerosis (MESA) obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) and does not necessarily reflect the opinions or views of ARIC, CHS, JHS, MESA, or NHLBI. An anonymised individual-participant data dataset from CREED was kindly provided by Prof. Zoccali, Prof. Tripepi, and Prof. Mallamaci from the Institute of Biomedicine (CNR), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy on the basis on their 'public use' policy. We thank the CREED group for sharing their valuable data. We are grateful to the team members of the VASCage project (FFG COMET K-Project 843536) for their support.

Disclosure Statement

L. Tschiderer reports grants from the Dr.-Johannes-and-Hertha-Tuba Foundation during the conduct of the study and non-financial support from Sanofi outside the submitted work. L. Seekircher reports non-financial support from Sanofi outside the submitted work. G. Klingenschmid reports non-financial support from Sanofi and Pfizer outside the submitted work. N. Sattar reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli-Lilly, Novo Nordisk, Sanofi, and Pfizer and grants from Boehringer Ingelheim outside the submitted work. S.E. Kjeldsen reports personal fees from Merck Darmstadt, MSD Whitehouse Station, Sanofi Paris, and Takeda Chicago outside the submitted work. S. Kiechl reports grants from Austrian Promotion Agency FFG outside the submitted work. G.D. Norata reports grants from Pfizer and Amgen and personal fees from Sanofi, Amgen, Alnylam, and Novartis outside the submitted work. P. Willeit reports grants from the Dr.-Johannes-and-Hertha-Tuba Foundation and the Austrian Science Fund FWF during the conduct of the study. Other authors have no conflicts of interest.

Funding Sources

This work has been funded by the Austrian Science Fund (FWF) [P 32488] and the Dr.-Johannes-and-Hertha-Tuba Foundation. Funders of individual studies contributing to the present analysis are listed on the Proof-ATHERO webpage (https://clinicalepi.i-med.ac.at/research/proof-athero/studies/).

Author Contributions

L. Tschiderer, L. Seekircher, G. Klingenschmid, and P. Willeit are part of the coordinating centre and are responsible for data management and data analysis of the Proof-ATHERO consortium. L. Tschiderer and L. Seekircher drafted the manuscript, conducted the analyses, and interpreted the data. G. Klingenschmid interpreted the data. M. J. Sweeting provided supervision for statistical analyses. P. Willeit is responsible for the conception and design of the work, drafted the manuscript, conducted the analyses, and interpreted the data. All other authors were responsible for data acquisition. All authors revised the manuscript critically for important intellectual content approved the final version of the manuscript.

Collaborators committee: Maria V. Manzi[1], Costantino Mancusi[1], Helmuth Steinmetz[2], Matthias Sitzer[2,3], Mauro Amato[4], Fabrizio Veglia[4], Elena Tremoli[4], Samuela Castelnuovo[5], Dong Zhao[6], Miao Wang[6], Stela McLachlan[7], Moo-Sik Lee[8,9], Hyun-Woong Park[9], Salim Yusuf[10,11], Diederick E. Grobbee[12], Frank L. J. Visseren[13], John J. P. Kastelein[14], Wiek van Gilst[15], Folkert W. Asselbergs[16], Muriel P. C. Grooteman[17], Peter J. Blankestijn[18], Ercan Ok[19], Giuseppe Guglielmini[20], Rino Migliacci[21], Lena Bokemark[22], Kazuo Kitagawa[23], Michael Skilton[24], Lisa M. Jamieson[25], Oscar Beloqui[26], David Preiss[27], Philip C. Calder[28,29], Lokpal Bhatia[28,29], Pieter M. ter Wee[17], Chrystosomos Dimitriadis[30], Radovan Hojs[31,32], Sebastjan Bevc[31,32], Peter Reiss[33,34], Marit G. A. van Vonderen[35], Ana R. Cunha[36], Mayuko Amaha[37], Tsukasa Nakamura[37], Tatyana Balakhonova[38], Maya Safarova[39], Jesse Dawson[40], Peter Higgins[40], Kristian Wachtell[41], Sverre E. Kjeldsen[41], Aleksandar Jovanovic[42], Tatjana Lazarevic[43], Aleksandra Araszkiewicz[44], Aleksandra Uruska[44], Dariusz Naskręt[44], Beat Frauchiger[45], Heiko Uthoff[46], Kazuomi Kario[47], Satoshi Hoshide[47], Erik Stroes[14], Edith Beishuizen[48], Tadao Akizawa[49], Thapat Wannarong[50,51], Sophia Zoungas[52], John McNeil[52], Alfonsa Friera[53], Carmen Suarez[54], Femke Rutters[55], Petra Elders[56], Coen D. A. Stehouwer[57],

Moise Desvarieux[58,59], Pierre Ducimetiere[60], Matthieu Plichart[61,62], Hertzel C. Gerstein[10,11], Ari Voutilainen[63], Jussi Kauhanen[63], Liliana Grigore[64], Giuseppe D. Norata[64,65], Ta-Chen Su[66], Pei-Chun Chen[67], Hung-Ju Lin[66], Holger Poppert[68], Horst Bickel[69], and M. Arfan Ikram[70].

Affiliations of members of the collaborators committee: [1]Department of Advanced Biochemical Sciences, Federico II University, Naples, Italy; [2]Department of Neurology, Goethe University, Frankfurt am Main, Germany; [3]Department of Neurology, Klinikum Herford, Herford, Germany; [4]Centro Cardiologico Monzino IRCCS, Milan, Italy; [5]Centro Dislipidemie, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; [6]Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; [7]Usher Institute, University of Edinburgh, Edinburgh, UK; [8]Department of Preventive Medicine, Konyang University, Daejeon, Korea; [9]College of Medicine, Konyang University Hospital, Daejeon, Korea; [10]Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; [11]Hamilton General Hospital, Hamilton, Ontario, Canada; [12]Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; [13]Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; [14]Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; [15]Department of Experimental Cardiology, University Medical Center Groningen, Groningen, the Netherlands; [16]Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands; [17]Department of Nephrology, Amsterdam UMC, Amsterdam, the Netherlands; [18]Department of Nephrology, University Medical Center Utrecht, Utrecht, the Netherlands; [19]Division of Nephrology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey; [20]Division of Internal and Cardiovascular Medicine, Department of Medicine, University of Perugia, Perugia, Italy; [21]Division of Internal Medicine, Cortona Hospital, Cortona, Italy; [22]Wallenberg Laboratory for Cardiovascular Research, University of Gothenburg, Gothenburg, Sweden; [23]Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; [24]Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Sydney, NSW 2006, Australia; [25]Australian Research Centre for Population Oral Health, University of Adelaide, Adelaide, SA, Australia; [26]Department of Internal Medicine, University Clinic of Navarra, Navarra, Spain; [27]MRC Population Health Research Unit, Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; [28]Faculty of Medicine, University of Southampton - Southampton General Hospital, Southampton, UK; [29]Southampton NIHR Biomedical Research Centre, University Hospital Southampton -

Southampton General Hospital, Southampton, UK; [30]University Department of Nephrology, Hippokration General Hospital, Thessaloniki, Greece; [31]Department of Nephrology, University Medical Centre Maribor, Maribor, Slovenia; [32]Faculty of Medicine, University of Maribor, Maribor, Slovenia; [33]Department of Global Health, Amsterdam UMC- Location AMC, Amsterdam, the Netherlands; [34]Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, the Netherlands; [35]Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, the Netherlands; [36]Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil; [37]Division of Nephrology, Shinmatsudo Central General Hospital, Chiba, Japan; [38]Ultrasound Vascular Laboratory, National Medical Research Center of Cardiology, Moscow, Russia; [39]Atherosclerosis Department, National Medical Research Center of Cardiology, Moscow, Russia; [40]Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; [41]Department of Cardiology, Oslo University Hospital, Oslo, Norway; [42]Faculty of Medicine, University of Prishtina, Prishtina\Kosovska Mitrovica, Serbia; [43]Faculty of Medicine, University of Kragujevac, Kragujevac, Serbia; [44]Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland; [45]Department of Internal Medicine, Kantonsspital Frauenfeld, Frauenfeld, Switzerland; [46]Department of Angiology, University Hospital Basel, Basel, Switzerland; [47]Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; [48]Department of Internal Medicine, HMC+ (Bronovo), the Hague, the Netherlands; [49]Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan; [50]Stroke Prevention & Atherosclerosis Research Centre, Western University, London, Canada; [51]Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; [52]School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; [53]Radiology Department, Universidad Autónoma de Madrid, Madrid, Spain; [54]Internal Medicine Department, Universidad Autónoma de Madrid, Madrid, Spain; [55]Department of Epidemiology & Biostatistics, Amsterdam UMC-Location Vumc, Amsterdam, the Netherlands; [56]Department of General Practice, Amsterdam UMC- Location Vumc, Amsterdam, the Netherlands; [57]Department of Internal Medicine and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands; [58]Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA; [59]METHODS Core, Centre de Recherche Epidémiologie et Statistique Paris Sorbonne Cité (CRESS), Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1153, Paris, France; [60]Faculty of Medicine, University Paris Descartes, Paris, France; [61]Paris Cardiovascular Research Centre (PARCC), University

Paris Descartes, Paris, France; [62]Assistance Publique, Hôpitaux de Paris, Hôpital Broca, Paris, France; [63]Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland; [64]SISA Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, Italy; [65]Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; [66]Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; [67]Clinical Informatics & Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan; [68]Department of Neurology, Technische Universität München, Munich, Germany; [69]Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany; [70]Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands

References

1 GBD 2017 Causes of Death Collaborators: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736–1788.

2 Enos WF, Holmes RH, Beyer J: Coronary disease among United States soldiers killed in action in Korea; preliminary report. J Am Med Assoc 1953;152:1090–1093.

3 McNamara JJ, Molot MA, Stremple JF, Cutting RT: Coronary artery disease in combat casualties in Vietnam. JAMA 1971;216:1185–1187.

4 Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317–325.

5 Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, et al.: Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999;30:841–850.

6 Müller-Scholden L, Kirchhof J, Morbach C, Breunig M, Meijer R, Rücker V, et al.: Segment-specific association of carotid-intima-media thickness with cardiovascular risk factors - findings from the STAAB cohort study. BMC Cardiovasc Disord 2019;19:84.

7 Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R: Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986;74:1399–1406.

8 Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen T-P, et al.: Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): A meta-analysis of individual participant data. Lancet 2012;379:2053–2062.

9 Den Ruijter HM, Peters SAE, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al.: Common carotid intima-media thickness measurements in cardiovascular risk prediction: A meta-analysis. JAMA 2012;308:796–803.

10 Kiechl S, Willeit J: The natural course of atherosclerosis. Part I: Incidence and progression. Arterioscler Thromb Vasc Biol 1999;19:1484–1490.

11 Kiechl S, Willeit J: The natural course of atherosclerosis. Part II: Vascular remodeling. Bruneck Study Group. Arterioscler Thromb Vasc Biol 1999;19:1491–1498.

12 Fowkes FGR, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al.: Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA 2008;300:197–208.

13 Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al.: Aortic pulse wave velocity improves cardiovascular event prediction: An individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2014;63:636–646.

14 Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, et al.: Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: Systematic review and meta-analysis. BMJ 2013;346:f1654.

15 Kavousi M, Desai CS, Ayers C, Blumenthal RS, Budoff MJ, Mahabadi A-A, et al.: Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis. JAMA 2016;316:2126–2134.

16 Chaikriangkrai K, Jhun HY, Palamaner Subash Shantha G, Bin Abdulhak A, Sigurdsson G, Nabi F, et al.: Coronary artery calcium score as a predictor for incident stroke: Systematic review and meta-analysis. Int J Cardiol 2017;236:473–477.

17 Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al.: The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015;241:507–532.

18 Rajzer MW, Wojciechowska W, Klocek M, Palka I, Brzozowska-Kiszka M, Kawecka-Jaszcz K: Comparison of aortic pulse wave velocity measured by three techniques: Complior, SphygmoCor and Arteriograph. J Hypertens 2008;26:2001–2007.

19 Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019;100:106.

20 Lorenz MW, Bickel H, Bots ML, Breteler MMB, Catapano AL, Desvarieux M, et al.: Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. Am Heart J 2010;159:730-736.e2.

21 Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, et al.: Carotid intima-media thickness progression and risk of vascular events in people with diabetes: Results from the PROG-IMT collaboration. Diabetes Care 2015;38:1921–1929.

22 Lorenz MW, Gao L, Ziegelbauer K, Norata GD, Empana JP, Schmidtmann I, et al.: Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. PLoS ONE 2018;13:e0191172.

23 Gray-Weale AC, Graham JC, Burnett JR, Byrne K, Lusby RJ: Carotid artery atheroma: comparison of preoperative B-mode ultrasound appearance with carotid endarterectomy specimen pathology. J Cardiovasc Surg (Torino) 1988;29:676–681.

24 Thompson S, Kaptoge S, White I, Wood A, Perry P, Danesh J: Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol 2010;39:1345–1359.

25 Jackson D, White I, Kostis JB, Wilson AC, Folsom AR, Wu K, et al.: Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med 2009;28:1218–1237.

26 Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM: Assessing risk prediction models using individual participant data from multiple studies. Am J Epidemiol 2014;179:621–632.

27 Sanderson J, Thompson SG, White IR, Aspelund T, Pennells L: Derivation and assessment of risk prediction models using case-cohort data. BMC Med Res Methodol 2013;13:113.

28 White IR: Multivariate random-effects meta-analysis. Stata Journal 2009;9:40–56. http://www.stata-journal.com/article.html?article=st0156.

29 Riley RD, Price MJ, Jackson D, Wardle M, Gueyffier F, Wang J, et al.: Multivariate meta-analysis using individual participant data. Res Synth Methods 2015;6:157–174.

30 Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H: Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005;6:3.

31 Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK: Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J 2010;160:701–714.

32 Costanzo P, Perrone-Filardi P, Vassallo E, Paolillo S, Cesarano P, Brevetti G, et al.: Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010;56:2006–2020.

33 O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older

568 adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med
569 1999;340:14–22.
570 34 Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, et al.: Carotid wall
571 thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities
572 (ARIC) study. Am. J. Epidemiol. 2000;151:478–487.
573 35 Lorenz MW, Kegler S von, Steinmetz H, Markus HS, Sitzer M: Carotid intima-media
574 thickening indicates a higher vascular risk across a wide age range: prospective data from
575 the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37:87–92.
576 36 Polak JF, Szklo M, O'Leary DH: Associations of Coronary Heart Disease with Common
577 Carotid Artery Near and Far Wall Intima-Media Thickness: The Multi-Ethnic Study of
578 Atherosclerosis. J Am Soc Echocardiogr 2015;28:1114–1121.
579 37 Lind L, Gigante B, Borne Y, Mälarstig A, Sundström J, Ärnlöv J, et al.: The plasma protein
580 profile and cardiovascular risk differ between intima-media thickness of the common
581 carotid artery and the bulb: A meta-analysis and a longitudinal evaluation. Atherosclerosis
582 2020;295:25–30.
583 38 Bots ML, Jong PTVM de, Hofman A, Grobbee DE: Left, Right, Near or Far Wall Common
584 Carotid Intima-Media Thickness Measurements: Associations with Cardiovascular Disease
585 and Lower Extremity Arterial Atherosclerosis. J Clin Epidemiol 1997;50:801–807.
586 39 Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JCM: Carotid intima-
587 media thickness at different sites: relation to incident myocardial infarction; The Rotterdam
588 Study. Eur Heart J 2002;23:934–940.
589 40 Tschiderer L, Klingenschmid G, Seekircher L, Willeit P: Carotid intima-media thickness
590 predicts carotid plaque development: Meta-analysis of seven studies involving 9,341
591 participants. Eur J Clin Invest 2020:e13217.
592 41 Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and
593 clinical relevance. Circulation 2007;115:1285–1295.
594

Figure Legends

Fig. 1. Measures for quantifying atherosclerosis.

Fig. 2. Data management and analysis workflow in the Proof-ATHERO consortium.

Fig. 3. Location of studies contributing data to the Proof-ATHERO consortium as of 24 January 2020. Full study names and references are provided in **Table S1**.

Table 1. Availability of atherosclerosis measures in the Proof-ATHERO consortium as of 24 January 2020

Study acronym or first author [Reference]	cIMT	Carotid diameter	Carotid plaque	ABI	PWV	CACS
General population						
AIR	●	●	●	○	○	○
ARIC	●	●	●	●	●	○
BRUN	●	●	●	●	○	○
CAPS	●	●	●	○	○	○
CCCC	●	○	●	○	○	○
CHS	●	●	●	●	○	○
CMCS-BEIJING	●	●	●	○	○	○
DIWA	●	●	⁕	○	○	○
EAS	●	○	●	⁕	○	○
EPICARDIAN	●	●	○	○	○	○
EVA	●	●	●	○	○	○
HOORN	●	⁕	○	⁕	⁕	○
INVADE	●	○	●	●	○	○
JHS	●	○	●	●	●	●
KIHD	●	○	●	○	○	○
MESA	●	⁕	●	●	○	●
NOMAS-INVEST	●	●	●	○	○	○
PIVUS	●	●	●	⁕	○	○
PLIC	●	○	●	○	○	○
ROTTERDAM	●	●	●	⁕	⁕	⁕
SAPHIR	●	●	●	○	○	○
High-risk populations						
BK REGISTRY	●	○	●	○	○	○
CREED	●	○	○	○	○	○
CSN	●	●	●	○	○	○
Ekart	●	○	⁕	○	○	○
HD-IMT	●	●	○	○	○	○
Honda	●	○	○	○	○	○
IMPROVE	●	●	●	○	○	○
Kato	●	○	●	⁕	⁕	○
Landecho	●	○	●	○	○	⁕
NIGUARDA-MONZINO	●	●	●	○	○	○
OSACA2	●	●	○	○	○	○
Papagianni	●	○	●	○	○	○
POPROSTU	●	●	○	○	○	○
RIAS	●	○	⁕	○	○	○
SPARC	●	○	●	○	○	○
3SCO	●	●	○	○	○	○

Study acronym or first author [Reference]	cIMT	Carotid diameter	Carotid plaque	ABI	PWV	CACS
Clinical trials						
ACAPS	●	○	○	○	○	○
ALLO-IMT	●	○	○	○	●	○
ASAP-NL	●	●	⁕	○	○	○
ATIC	●	○	○	○	○	○
AUDITOR	●	○	○	○	○	○
BAS	●	○	○	○	●	○
BK REGISTRY II	●	○	●	○	○	○
CAMERA	●	○	●	○	○	○
CAPTIVATE	●	●	○	○	○	○
CERDIA	●	○	○	○	○	○
CONTRAST	●	○	●	○	○	○
EGE STUDY	●	○	●	○	⁕	⁕
ENHANCE	●	○	●	○	○	○
FACIT	●	●	○	○	○	○
GRACE	●	○	⁕	⁕	○	○
Gresele	●	○	○	⁕	○	○
HART	●	○	⁕	⁕	○	○
KIMVASC	●	○	○	○	⁕	○
LIFE-ICARUS	●	●	●	○	○	○
Masia	●	○	●	●	○	○
MAVET	●	○	○	○	○	○
MEDICLAS	●	●	○	○	⁕	○
MG600	●	●	●	○	●	○
Nakamura II	●	●	⁕	○	⁕	○
OPAL	●	⁕	○	○	○	○
PERIOCARDIO	●	●	○	○	⁕	○
PREVEND IT	●	○	○	○	○	○
RADIANCE I	●	●	○	○	○	○
RADIANCE II	●	●	○	○	○	○
REGRESS	●	○	○	○	○	○
RIS	●	●	⁕	○	○	○
Safarova	●	○	⁕	⁕	⁕	○
SECURE	●	○	⁕	⁕	○	○
STARR	●	○	⁕	⁕	○	○
STOP-NIDDM	●	○	○	○	○	○
VITAL	●	○	○	○	○	○
WELCOME	●	○	●	○	○	○

● =available and provided, ⁕ =available but not provided, ○ =not available. ABI, ankle-brachial index; CACS, coronary artery calcium score; cIMT, carotid intima-media thickness; PWV, pulse wave velocity. Full study names and references are provided in **Table S1**.

Table 2. Design and descriptive summary of studies in the Proof-ATHERO consortium

Study acronym or first author	Country	Population source	Population type	Years of baseline	No.	♀, %	Mean age, years (SD)
General population							
AIR	Sweden	Population register	General population	1995-97	391	0	58 (0.1)
ARIC	USA	Household listings	General population	1986-90	15,121	55	54 (6)
BRUN	Italy	Population register	General population	1990	933	49	59 (11)
CAPS	Germany	Electoral rolls	General population	1995-00	6,970	51	51 (13)
CCCC	Taiwan	Community screening	General population	1990-91	3,602	53	55 (12)
CHS	USA	Medicare lists	General population	1989-93	5,888	57	73 (6)
CMCS-BEIJING	China	Population register	General population	2002	1,324	53	60 (8)
DIWA	Sweden	Population register	General population	2001-04	644	100	64 (0.3)
EAS	Scotland	GP lists	General population	1987-88	1,115	50	64 (6)
EPICARDIAN	Spain	Population register	General population	1993-04	446	59	68 (12)
EVA	France	Electoral rolls	General population	1992-93	1,135	59	65 (3)
HOORN	Netherlands	Population register	General population	1999-01	780	50	69 (7)
INVADE	Germany	Insurance company	General population	2001-03	3,908	59	68 (8)
JHS	USA	Household listings	General population	2000-04	3,883	63	55 (13)
KIHD	Finland	Population register	General population	1987-89	1,399	0	52 (6)
MESA	USA	Household listings	General population	2000-02	6,814	53	62 (10)
NOMAS-INVEST	USA	Random digit dialing	General population	1993-01	856	62	66 (8)
PIVUS	Sweden	Population register	General population	2001-04	1,016	50	70 (0.0)
PLIC	Italy	Hospital	General population	1998-03	1,782	59	55 (11)
ROTTERDAM	Netherlands	Population register	General population	1990-93	7,983	61	71 (10)
SAPHIR	Austria	GP lists/advert	General population	1999-02	1,794	37	52 (6)
High-risk populations							
BK REGISTRY	Korea	Hospital	CHD	2000-07	1,000	44	60 (10)
CREED	Italy	Hospital	On haemodialysis/CAPD	1997-98	138	41	60 (16)
CSN	Italy	GP lists	Hypertension	1980-14	14,158	44	53 (13)
Ekart	Slovenia	Hospital	On haemodialysis	1996-05	54	50	55 (15)
HD-IMT	Serbia	Hospital	On haemodialysis	2004-05	85	39	59 (12)
Honda	Japan	Hospital	On haemodialysis	2005-07	313	39	61 (13)
IMPROVE	Multinational	Hospital/community screening	≥3 CVD RFs	2004-05	3,703	52	64 (5)
Kato	Japan	Hospital	On haemodialysis	2008-09	284	30	64 (12)
Landecho	Spain	Hospital	Early kidney disease	1999-11	250	12	55 (10)
NIGUARDA-MONZINO	Italy	Hospital	Lipid clinic patients/ CVD RFs	1984-10	1,564	41	56 (12)
OSACA2	Japan	Hospital	≥1 atherosclerotic RF	2000-03	291	40	65 (9)
Papagianni	Greece	Hospital	On haemodialysis	2001	83	46	58 (15)
POPROSTU	Poland	Hospital	T1DM	1999	96	33	24 (6)
RIAS	Switzerland	Hospital	≥1 CVD RF/CVD	1999-00	145	43	64 (13)
SPARC	Canada	Hospital	Carotid plaque	2006-08	349	43	71 (9)
3SCO	Japan	Hospital	≥1 CVD RF	2007	164	74	80 (6)
Clinical trials							
ACAPS	USA	Mailing lists/ community screening	LDL-C 130-189 mg/dL	1989-90	919	48	62 (8)
ALLO-IMT	Scotland	Hospital	Ischaemic stroke/TIA	2009-10	80	43	68 (10)
ASAP-NL	Netherlands	Hospital	Heterozygous FH	1997-98	325	61	49 (11)
ATIC	Netherlands	Hospital	Chronic renal failure	2001-02	93	43	53 (12)
AUDITOR	Multinational	Hospital	Obesity+metabolic syndrome	2005-06	661	49	63 (6)
BAS	China	Community screening	cIMT↑	2010	125	63	57 (5)
BK REGISTRY II	Korea	Hospital	Coronary stent	2000-03	205	32	60 (10)
CAMERA	Scotland	Hospital/GP lists	CHD	2009-11	173	23	63 (8)
CAPTIVATE	Multinational	Hospital	Heterozygous FH	2004-05	719	NP	NP
CERDIA	Netherlands	Hospital	T2DM	1999-01	250	53	58 (11)
CONTRAST	Multinational	Hospital	On haemodialysis	2004-09	714	38	64 (14)

EGE STUDY	Turkey	Hospital	On haemodialysis	2005-06	644	46	59 (14)
ENHANCE	Multinational	Hospital	Heterozygous FH	2002-06	720	49	47 (9)
FACIT	Netherlands	Municipal/blood bank registries	General population	2000-01	819	28	60 (6)
GRACE	Multinational	Hospital	Dysglycaemia+CVD RFs/CVD	2003-05	1,189	36	63 (8)
Gresele	Multinational	Hospital	Peripheral arterial disease	2003-05	442	21	67 (9)
HART	Canada	Hospital/GP lists	CVD/DM+≥1 CVD RF	1999-00	925	24	69 (7)
KIMVASC	Scotland	GP lists	CVD/hypertension/DM	2011-12	80	45	77 (5)
LIFE-ICARUS	Multinational	Hospital	Hypertension+LVH	1996-97	83	27	67 (6)
Masia	Spain	Hospital	HIV+≥2 CVD RFs	2006-07	68	10	52 (11)
MAVET	Australia	Newspaper advert	Smokers	1994-95	408	54	64 (6)
MEDICLAS	Multinational	Hospital	HIV	2003-05	48	0	42 (10)
MG600	Brazil	Hospital	Hypertension	2010-11	35	100	55 (7)
Nakamura II	Japan	Hospital	Chronic renal failure	2001	50	40	53 (7)
OPAL	Multinational	Hospital/GP lists/other[a]	General population	1997-99	866	100	59 (7)
PERIOCARDIO	Australia	Health facilities	Aboriginal Australians	2010-12	273	42	41 (10)
PREVEND IT	Netherlands	Population register	Microalbuminuria	1998-99	864	35	51 (12)
RADIANCE I	Multinational	Hospital	Heterozygous FH	2003-04	904	51	46 (13)
RADIANCE II	Multinational	Hospital	Mixed dyslipidaemia	2003-06	752	36	57 (8)
REGRESS	Netherlands	Hospital	CHD+TC 155-310 mg/dL	1989-91	255	0	56 (8)
RIS	Sweden	Hospital	Hypertension+≥1 CVD RF	1987-89	164	0	66 (5)
Safarova	Russia	Hospital	CHD	2007-09	60	0	55 (6)
SECURE	Canada	Hospital	CVD/DM+≥1 CVD RF	1994-95	731	24	66 (7)
STARR	Multinational	Hospital/GP lists/other[b]	Dysglycaemia	2001-03	1,320	55	53 (11)
STOP-NIDDM	Germany	High-risk population screening	Dysglycaemia	1996-98	119	42	54 (7)
VITAL	Netherlands	Hospital	Indication for statin use	2002-04	199	41	49 (12)
WELCOME	UK	Hospital	NAFLD	2010-11	103	42	51 (11)
Total				**1980-14**	**106,846**	**50**	**59 (10)**

CAPD, continuous ambulatory peritoneal dialysis; CHD, coronary heart disease; cIMT, carotid intima-media thickness; CVD, cardiovascular disease; DM, diabetes mellitus; FH, familial hypercholesterolaemia; GP, general practitioner; HIV, human immunodeficiency virus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; NAFLD, non-alcoholic fatty liver disease; NP, not provided; RF, risk factor; SD, standard deviation; TC, total cholesterol; TIA, transient ischaemic attack; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. Full study names and references are provided in **Table S1**. [a]Existing ongoing population-based cohorts and advertisements in local print and broadcast media. [b]Public advertising and news reports in the media, internet items, referral from relatives, poster displays, diabetes screening fairs and direct mailing campaigns.

Carotid ultrasound





Pulse wave velocity



$$PWV = \frac{\Delta L}{\Delta T}$$



Ankle-brachial index

Coronary artery calcium




Coordinating centre & steering committee
Study collaborators
Request study data
Decide about joining
Implement data
Sign contract & share data
Perform data cleaning
Process any data queries
Add to central database
Define projects
Draft analysis plan
Comment on analysis plan
Draft manuscript
Comment on manuscript
Finalise manuscript
Submit for publication


Proof-ATHERO
MEDICLAS
CAPTIVATE
VITAL
ASAPNL
KIMVASC
AUDITOR
RADIANCEI
LIFEICARUS
KIHD
CAMERA
ATIC
RADIANCEII
RIS
PIVUS
ALLOIMT
ENHANCE
PREVENDIT
DIWA
EAS
REGRESS
OPAL
AIR
POPROSTU
WELCOME
CERDIA
CONTRAST
STOPNIDDM
ROTTERDAM
FACIT
CAPS
INVADE
SAPHIR
EVA
RIAS
HOORN
Ekart
BRUN
PLIC
NIGUARDAMONZINO
Gresele
HDIMT
Landecho
EPICARDIAN
IMPROVE
CSN
Papagianni
Masia
CREED
EGESTUDY
GRACE
HART
STARR
CHS
SPARC
SECURE
JHS
ARIC
NOMASINVEST
ACAPS
MESA
Safarova
CMCSBEIJING
BAS
3SCO
Nakamurall
BKREGISTRYII
Honda
OSACA2
Kato
BKREGISTRY
CCCC
MG600
PERIOCARDIO
MAVET
General population
High-risk population
Clinical trial

The Prospective Studies of Atherosclerosis (Proof-ATHERO) consortium: Design and rationale

Tschiderer, Seekircher *et al.*

Electronic Supplementary Material

Table S1. Study acronyms, full study names, and study references in the Proof-ATHERO consortium

Study acronym or first author	Ref.	Full study name
General population		
AIR	[1]	Atherosclerosis and Insulin Resistance Study
ARIC	[2]	Atherosclerosis Risk in Communities Study
BRUN	[3]	Bruneck Study
CAPS	[4]	Carotid Atherosclerosis Progression Study
CCCC	[5]	Chin-Shan Community Cardiovascular Cohort
CHS	[6]	Cardiovascular Health Study
CMCS-BEIJING	[7]	Chinese Multi-Provincial Cohort Study (Beijing)
DIWA	[8]	Diabetes and Insulin Resistance in Women Study
EAS	[9]	Edinburgh Artery Study
EPICARDIAN	[10]	Epidemiología Cardiovascular en los Ancianos en España Study
EVA	[11]	Étude sur la Vieillissement Artériel Study
HOORN	[12]	Hoorn Study
INVADE	[13]	Interventionsprojekt zerebrovaskuläre Erkrankungen und Demenz im Landkreis Ebersberg
JHS	[14]	Jackson Heart Study
KIHD	[15]	Kuopio Ischemic Heart Disease Risk Factor Study
MESA	[16]	Multi-Ethnic Study of Atherosclerosis
NOMAS-INVEST	[17]	Northern Manhattan Study and The Oral Infections and Vascular Disease Epidemiology Study
PIVUS	[18]	Prospective Investigation of the Vasculature in Uppsala Seniors Study
PLIC	[19]	Presence and Progression of Lesions in Carotid Arteries Study
ROTTERDAM	[20]	Rotterdam Study
SAPHIR	[21]	Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk
High-risk populations		
BK REGISTRY	[22]	BK Registry Study
CREED	[23]	Cardiovascular Risk Extended Evaluation in Dialysis Patients
CSN	[24]	Campania Salute Network
Ekart	[25]	Study Ekart et al.
HD-IMT	[26]	HD-IMT Study
Honda	[27]	Study Honda et al.
IMPROVE	[28]	Carotid Intima Media Thickness and IMT-Progression as Predictors of Vascular Events in a High Risk European Population Study
Kato	[29]	Study Kato et al.
Landecho	[30]	Study Landecho et al.
NIGUARDA-MONZINO	[31]	Niguarda-Monzino Study
OSACA2	[32]	Osaka Follow-up Study for Carotid Atherosclerosis 2
Papagianni	[33]	Study Papagianni et al.
POPROSTU	[34]	Poznań Prospective Study of Type-1 Diabetic Patients
RIAS	[35]	Resistive Index in Atherosclerosis Study
SPARC	[36]	SPARC Study
3SCO	[37]	Hiroshima-Shobara-Soryo Cohort
Clinical trials		
ACAPS	[38]	Asymptomatic Carotid Artery Progression Study
ALLO-IMT	[39]	ALLO-IMT Study
ASAP-NL	[40]	Atorvastatin vs. Simvastatin on Atherosclerosis Progression Study
ATIC	[41]	Anti-oxidant Therapy in Chronic Renal Insufficiency Study
AUDITOR	[42]	Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in atients on Rimonabant Study
BAS	[43]	Beijing Atherosclerosis Study
BK REGISTRY II	[44]	BK Registry II Study
CAMERA	[45]	Carotid Atherosclerosis - Metformin for Insulin Resistance Study
CAPTIVATE	[46]	Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition
CERDIA	[47]	Cerivastatin in Diabetes Trial
CONTRAST	[48]	Convective Transport Study
EGE STUDY	[49]	Ege Study

ENHANCE	[50]	Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis egression Trial
FACIT	[51]	Folic Acid and Carotid Intima-media Thickness Study
GRACE	[52]	Glucose Reduction and Atherosclerosis Continuing Evaluation Study
Gresele	[53]	Study Gresele at al.
HART	[54]	Homocysteine and Atherosclerosis Reduction Trial
KIMVASC	[55]	KIMVASC Study
LIFE-ICARUS	[56]	Losartan Intervention For Endpoint Reduction in Hypertension - Insulin Carotids US Scandinavia Study
Masia	[57]	Study Masiá et al.
MAVET	[58]	Melbourne Atherosclerosis Vitamin E Trial
MEDICLAS	[59]	Metabolic Effects of Different Classes of Antiretrovirals Study
MG600	[60]	Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients Study
Nakamura II	[61]	Study Nakamura et al. II
OPAL	[62]	Osteoporosis Prevention and Arterial Effects of Tibolone Study
PERIOCARDIO	[63]	PerioCardio Study
PREVEND IT	[64]	Prevention of Renal and Vascular Endstage Disease Intervention Trial
RADIANCE I	[65]	Rating Atherosclerosis Disease Change by Imaging with a New CETP Inhibitor 1 Trial
RADIANCE II	[66]	Rating Atherosclerosis Disease Change by Imaging with a New CETP Inhibitor 2 Trial
REGRESS	[67]	Regression Growth Evaluation Statin Study
RIS	[68]	Risk Factor Intervention Study
Safarova	[69]	Study Safarova at al.
SECURE	[70]	Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E
STARR	[71]	Study of Atherosclerosis with Ramipril and Rosiglitazone
STOP-NIDDM	[72]	Study to Prevent Non-Insulin-Dependent Diabetes Mellitus
VITAL	[73]	Vital Study
WELCOME	[74]	Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with Omacor Therapy Trial

Table S2. Ascertainment of cIMT in the Proof-ATHERO consortium

Study acronym or first author	cIMT definition											Measurement features							
	Section			Side			Wall			Type									
	CCA	BIF	ICA	Right	Left	Average	Near	Far	Average	Mean	Max	Plaque avoided	Multiple scans	ECG gated	Same machine type	Same sonographer	Central reading	Angle control	Edge detection
General population																			
AIR	●	●	○	●	●	●	○	●	●	●	●	–	–	+	+	+	+	–	+[e]
ARIC	●	●	●	●	●	●	●	●	●	●	●	–	+	+	+	–	+	+	–
BRUN	●	●	●	●	●	●	○	●	●	●	●	+	–	+	–	+	–	+	–
CAPS	●	●	●	●	●	●	○	●	●	●	○	–	–	+	+	–	+	–	+[d]
CCCC	●	○	●	●	●	●	○	●	●	○	●	+	+	+	+	–	–	+	–
CHS	●	○	●	●	●	●	●	●	●	○	●	–	+[a]	–	+	–	+	+	–
CMCS-BEIJING	●	●	●	●	●	●	○	○	●	●	●	+	–	–	–	–	+	+	–/+[e]
DIWA	●	●	○	●	●	●	○	●	●	●	●	–	–	+	+	+	+	–	+[e]
EAS	●	○	○	●	●	●	○	●	●	●	●	–	–	–	+	–	+	–	–
EPICARDIAN	●	●	●	●	●	●	○	●	●	●	○	+	+	–	+	+	–	+	–
EVA	●	○	○	●	●	●	○	●	●	●	○	+	–	–	+	–	+	+	+[d]
HOORN	●	○	○	●	○	●	○	●	●	●	○	+	+	+	+	+	+	+	+[d]
INVADE	●	○	○	●	●	●	○	●	●	●	○	+	+	–	+	+	+	+	+[d]
JHS	●	●	●	●	●	●	●	●	●	●	●	–	+	+	+	–	+	+	–
KIHD	●	○	○	●	●	●	○	●	●	●	●	–	–	–	–	–	+	+	+[e]
MESA	●	○	●	●	●	●	○	○	●	●	●	+	+[ab]	+	+	NR	+	+	+[d]
NOMAS-INVEST	●	●	●	●	●	●	●	●	●	●	●	+	+[b]	–	+	+	+	+	+[e]
PIVUS	●	○	○	●	●	●	○	●	●	●	●	NR	–	+	+	+	+	–	+[e]
PLIC	●	○	○	●	●	●	○	●	●	●	●	+	+[b]	+	+	+	+	–	+
ROTTERDAM	●	○	○	●	●	●	●	●	●	●	●	–	+	+	+	–	+	–	–
SAPHIR	●	●	●	●	●	●	○	○	●	●	○	+	+	–	+	+	+	+	–
High-risk populations																			
BK REGISTRY	●	●	○	●	●	●	○	●	●	●	○	+	+	+	+	+	+	+	+[e]
CREED	●	○	○	○	○	●	○	●	●	●	○	+	–	+	+	+	–	+	–
CSN	●	●	●	●	●	●	●	●	●	○	●	–	–	–	+	–	+	–	–
Ekart	●	●	●	●	●	●	○	●	●	●	○	+	+	–	+	+	+	+	–
HD-IMT	●	○	○	●	○	●	○	●	●	○	●	–	–	+	+	+	–	–	–
Honda	●	○	○	●	●	●	○	●	●	●	●	–	–	–	–	–	–	–	–
IMPROVE	●	●	●	●	●	●	○	●	●	●	●	–	+	+[b]	+	–	+	+	+[e]
Kato	●	○	○	○	○	●	○	●	●	●	●	+	–	–	+	+	+	+	+[e]
Landecho	●	○	○	●	●	●	○	○	●	○	●	+	–	–	–	–	–	–	–
NIGUARDA-MONZINO	●	●	●	●	●	●	●	●	●	○	●	–	–	–	–	–	–	+	–
OSACA2	●	●	●	●	●	●	●	●	●	●	●	–	+[b]	–	+	–	+	–	–
Papagianni	○	●	○	●	●	●	○	●	●	●	●	+	–	+	+	+	+	–	–
POPROSTU	●	○	○	●	○	●	○	●	●	●	●	+	+	–	+	+	+	+	+[d]
RIAS	●	○	○	●	●	●	○	●	●	●	○	+	+	+	+	–	–	–	–
SPARC	●	○	○	●	●	●	○	●	●	●	○	+	+	–	NR	NR	+	–	–
3SCO	●	●	●	●	●	●	●	●	●	●	●	–	–	–	+	–	–	–	–
Clinical trials																			
ACAPS	●	●	●	●	●	●	○	○	●	○	●	–	–	+	+	–	+	+	+[e]
ALLO-IMT	●	●	●	●	●	●	●	●	●	●	●	–	–	+	+	+	+	+	+[de]
ASAP-NL	●	●	●	●	●	●	●	●	●	●	○	–	–	–	+	–	+	+	+[e]
ATIC	●	○	○	●	○	●	○	●	●	●	○	+	+	+	+	+	+	–	+[d]
AUDITOR	●	●	●	●	●	●	○	●	●	●	○	–	–	+	+	–	+	+	–
BAS	●	○	○	○	○	●	●	○	●	●	○	+	–	–	+	–	+	–	–
BK REGISTRY II	●	●	●	○	●	●	○	●	●	●	○	+	+	+	+	+	+	+	+[e]
CAMERA	●	○	○	●	●	●	○	●	●	●	○	+	–	+	+	+	+	+	+[e]
CAPTIVATE	●	●	●	●	●	●	●	●	●	●	●	–	+	–	+	–	+	+	+[e]
CERDIA	●	●	●	●	○	●	○	○	●	●	●	+	–	+	+	–	+	+	+[e]
CONTRAST	●	○	○	●	●	●	●	●	●	●	●	–	+	+	–	–	+	+	–

EGE STUDY	●	○	○	●	●	●	○	●	●	●	○	+	NR	NR	+	+	NR	NR	NR
ENHANCE	●	●	●	●	●	●	○	●	●	●	●	–	+[c]	–	+	–	+	+	+[e]
FACIT	●	○	○	○	○	●	○	○	●	●	●	–	+	+	+	–	+	+	+[d]
GRACE	●	●	●	●	●	●	●	●	●	●	●	–	+	–	–	–	+	+	–
Gresele	●	○	○	●	○	●	●	○	●	●	●	+	–	–	+	+	+	+	+[d]
HART	●	●	●	●	●	●	●	●	●	●	●	–	+	–	–	–	+	+	–
KIMVASC	●	○	○	●	●	●	○	●	●	●	○	+	–	–	+	+	+	–	–
LIFE-ICARUS	●	○	○	●	●	●	○	●	●	●	○	+	+[b]	+	+	+	+	+	+[e]
Masia	●	○	○	●	●	●	○	●	●	●	●	NR	NR	NR	NR	NR	NR	NR	NR
MAVET	●	○	○	○	○	●	○	○	●	○	●	NR	+	+	+	+	+	+	–
MEDICLAS	●	○	○	●	○	●	○	○	●	●	○	+	+	–	+	+	+	–	–
MG600	●	○	○	●	●	●	○	○	●	●	●	+	+	+	+	+	–	–	–
Nakamura II	●	●	●	●	●	●	○	●	●	●	●	+	–	+	+	+	+	+	–
OPAL	●	●	●	●	●	●	●	●	●	●	●	–	+	+	+	–	+	+	–
PERIOCARDIO	●	○	○	●	●	●	○	●	●	●	●	–	+	+	+	–	+	+	+[e]
PREVEND IT	●	○	○	○	●	●	○	●	●	●	○	+	+	+	+	–	+	+	+[d]
RADIANCE I	●	●	●	●	●	●	●	●	●	●	●	–	+[c]	+	+	–	+	+	+[e]
RADIANCE II	●	●	●	●	●	●	●	●	●	●	●	–	+[c]	+	+	–	+	+	+[e]
REGRESS	●	●	●	●	●	●	●	●	●	●	●	–	–	–	–	–	+	+	+[d]
RIS	●	●	○	●	○	●	○	●	●	●	●	+	+	+	+	+	+	+	+[d]
Safarova	●	○	○	●	●	●	○	●	●	●	○	+	–	+	+	+	+	+	+[e]
SECURE	●	●	●	●	●	●	●	●	●	○	●	–	+	–	–	–	+	+	–
STARR	●	●	●	●	●	●	●	●	●	●	●	–	+	–	–	–	+	+	–
STOP-NIDDM	●	○	○	●	●	●	○	●	●	●	●	NR	+	+	+	–	NR	NR	NR
VITAL	●	○	○	●	○	●	○	●	●	●	○	NR	NR	NR	NR	NR	NR	NR	NR
WELCOME	●	○	○	●	●	●	○	●	●	●	○	+	+	+	+	+	+	+	+[d]

●=provided, ○=not provided; BIF=carotid bifurcation, CCA=common carotid artery, cIMT=carotid intima-media thickness, ECG=electrocardiography, ICA=internal carotid artery, IMT=intima-media thickness. Full study names and references are provided in **Table S1**. [a]ICA only. [b]Only in a subset of the study population. [c]Only at baseline and final follow-up. [d]Automated. [e]Semi-automated.

Table S3. Ascertainment of carotid plaque in the Proof-ATHERO consortium

Study acronym or first author	Parameters					Detailed information on carotid plaque definition
	Status	Amount	Thickness	Area	Density[a]	
General population						
AIR	●	●	●	●	●	Distinct area with an IMT >50% thicker than that of neighbouring sites
ARIC	●	●	○	○	○	If two of three conditions are met: (1) wall shape (protrusion into the lumen, loss of alignment, rough boundary), (2) wall texture (brighter echoes than adjacent boundaries), and (3) wall thickness (IMT ≥1.5 mm)
BRUN	●	●	●	○	○	Based on (1) wall surface (protrusion into the lumen or roughness of the arterial boundary) and (2) wall texture (echogenicity)
CAPS	●	○	○	○	○	Focal protrusion of ≥1.8 mm
CCCC	●	●	○	○	○	Grading as (1) normal or no observable plaque, (2) one small plaque with diameter stenosis <30%, (3) one medium plaque with 30-49% diameter stenosis or multiple small plaques, (4) one large plaque with 50-99% diameter stenosis or multiple plaques with at least one medium plaque, and (5) 100% occlusion
CHS	●	○	○	○	●	Definition based on the greatest wall protrusion (i.e. IMT) and grading based on lesion surface, echogenicity, and texture characteristics as (1) no plaque (i.e. smooth surface and normal density and morphology), (2) high-risk plaque (i.e. irregular/ulcerated surface, echolucent, or heterogeneous texture), and (3) intermediate-risk plaque (i.e. any other combinations of lesion characteristics)
CMCS-BEIJING	●	○	●	●	○	IMT ≥1.3 mm or focal structure encroaching into arterial lumen of ≥0.5 mm or ≥50% of surrounding IMT
EAS	●	○	●	○	○	IMT >1.2 mm with advanced atherosclerotic plaque defined as IMT >2 mm
EVA	●	●	●	○	○	Localised echo structures encroaching into the vessel lumen with a distance ≥1 mm between media-adventitia interface and lesion surface facing the lumen
INVADE	●	○	○	○	○	Focal structure encroaching into the arterial lumen ≥0.5 mm or ≥50% of the surrounding IMT, or IMT >1.5 mm as measured from the media-adventitia interface to the intima-lumen interface
JHS	●	○	○	○	○	If two of three conditions are met: (1) wall shape (protrusion into the lumen, loss of alignment, rough boundary), (2) wall texture (brighter echoes than adjacent boundaries), and (3) wall thickness (IMT ≥1.5 mm)
KIHD	●	○	○	○	○	Distinct area either with mineralisation (bright echo, often producing a typical echogenic shadow) or with focal protrusion into the lumen
MESA	●	○	○	○	●	Discrete, focal thickening ≥1.5 mm or ≥50% greater than the surrounding IMT
NOMAS-INVEST	●	●	●	●	○	Focal wall thickening or protrusion into the lumen >50% greater than the surrounding thickness
PIVUS	●	○	●	●	○	Local thickening of the intima-media by >50% vs. surrounding IMT
PLIC	●	○	○	○	○	Focal plaque >1.3 mm in longitudinal resolution, lateral, or medial angle
ROTTERDAM	●	○	○	○	○	Focal widening relative to adjacent segments, with protrusion into the lumen with calcified deposits or both calcified and non-calcified material
SAPHIR	●	○	○	○	○	Grading as (1) normal, (2) vessel wall thickening <1 mm, (3) one minimal plaque ≤2 mm, (4) two moderate plaques ≤3 mm, (5) severe plaque >3 mm, and (6) completely obstructed lumen
High-risk populations						
BK REGISTRY	●	○	●	○	○	Focal structure encroaching into arterial lumen by ≥50% of surrounding IMT or thickness >1.2 mm
CSN	●	○	○	○	○	IMT >1.5 mm
IMPROVE	●	●	●	●	○	IMT ≥1.5 mm
Kato	●	○	○	○	○	IMT >1 mm
Landecho	●	○	○	○	○	Echogenic structures encroaching on the vessel's lumen with a distinct area 50% greater than the IMT of neighbouring sites
NIGUARDA-MONZINO	●	●	●	○	○	IMT ≥1.5 mm
Papagianni	●	○	○	○	○	Faint grey echoes or bright white echoes protruding into the arterial lumen
SPARC	●	○	○	●	○	Focal thickening >1 mm
Clinical trials						
BK REGISTRY II	●	○	●	○	○	Localised thickening >1.2 mm not involving the whole carotid artery
CAMERA	●	●	○	○	○	IMT ≥1.5 mm or focal encroachment into the arterial lumen ≥0.5 mm

CONTRAST	●	●	○	○	○	Grading as (1) no plaque, (2) minimal plaque, (3) moderate plaque, and (4) severe plaque, where a moderate or severe plaque was generally defined as a focal structure that encroaches into the arterial lumen or demonstrates a thickness >1.5 mm
EGE STUDY	●	○	●	○	○	NR
ENHANCE	●	○	○	○	○	IMT >1.3 mm
LIFE-ICARUS	●	○	○	○	○	Semi-quantitative grading of the amount of atherosclerotic lesions as (1) none, (2) very few, (3) few, (4) some, and (5) several
Masia	●	○	○	○	○	NR
MG600	●	○	○	○	○	IMT ≥1.5 mm
WELCOME	●	○	○	○	○	Focal thickening ≥50% greater than the surrounding wall or focal region with IMT >1.5 mm protruding into the lumen distinct from adjacent boundary

●=provided, ○=not provided; IMT, intima-media thickness; NR, not reported. Full study names and references are provided in **Table S1**. [a]Density according to the Gray-Weale classification.

Table S4. Assessment of prevalent and incident disease in the Proof-ATHERO consortium

Study acronym or first author	Prevalent disease			Incident events		
	CHD	Stroke	Diabetes	CHD	Stroke	Death
General population						
AIR	+	+	++	++	++	*
ARIC	++	++	++	++	++	**
BRUN	++	++	++	++	++	**
CAPS	+	+	+	++	++	**
CCCC	++	++	++	NR	++	*
CHS	++	++	++	++	++	**
CMCS-BEIJING	++	++	++	++	++	**[c]
DIWA	+	+	++	++	++	*
EAS	++	+	+	++	++	**[c]
EPICARDIAN	++	++	++	++	++	*
EVA	+	+	++	++[b]	++[b]	**
HOORN	+/++	+/++	++	++	++	**
INVADE	++	++	++	++	++	**
JHS	+	+	++	+	+	–[a]
KIHD	++	+	++	++	++	**
MESA	+	–[a]	++	++	++	**
NOMAS-INVEST	+	+	++	++	++	**
PIVUS	+	+	+/++	++	++	**
PLIC	NR	NR	++	NR	NR	NR
ROTTERDAM	++	++	++	++	++	**
SAPHIR	++	++	++	++	++	**
High–risk populations						
BK REGISTRY	++	–	++	++	++	*/**
CREED	NR	NR	NR	++	++	**
CSN	++	++	++	++	++	**
Ekart	NR	–	NR	NR	NR	NR
HD-IMT	NR	NR	NR	NR	NR	NR
Honda	NR	++	NR	++[b]	++[b]	**
IMPROVE	++	++	++	++	++	**
Kato	++	++	++	++	++	**
Landecho	++	++	++	++	++	**
NIGUARDA-MONZINO	++	++	++	++	++	**
OSACA2	+	+	++	++	++	*
Papagianni	++	+	++	++	+	*/**
POPROSTU	++	+	++	++	++	*
RIAS	++	++	++	++	++	**
SPARC	NR	NR	NR	++	++	**
3SCO	++	++	++	++	++	**
Clinical trials						
ACAPS	+	+	+	++	++	**
ALLO-IMT	+	++	+	++	++	*
ASAP-NL	–	–	++	–	–	–
ATIC	+/++	+/++	+/++	–[a]	–[a]	–[a]
AUDITOR	–	–	++	–	–	–
BAS	+	+	+	–	+	–
BK REGISTRY II	++	–	++	++	++	*/**
CAMERA	++	+	++	++	++	**
CAPTIVATE	–	–	++	–	–	–
CERDIA	++	–	++	++	++	**
CONTRAST	+	+	+	++	++	**
EGE STUDY	NR	NR	NR	++	++	**
ENHANCE	–[a]	++	++	++	++	**
FACIT	+	+	+	–	–	*
GRACE	++	++	++	++	++	**
Gresele	++	++	++	++	++	**
HART	++	++	++	++	++	**
KIMVASC	–[a]	–[a]	NR	NR	–	NR

LIFE-ICARUS	++	++	++	++	++	**
Masia	NR	NR	++	NR	–	NR
MAVET	–[a]	–[a]	–[a]	–	–	–
MEDICLAS	–	–	–	+	+	*
MG600	++	++	++	++	++	**
Nakamura II	NR	NR	NR	NR	NR	NR
OPAL	+	+	+	+	+	*
PERIOCARDIO	+	+	+	+	+	**
PREVEND IT	+	–[a]	+	++	++	*
RADIANCE I	+	–	++	++	++	**
RADIANCE II	+	–	++	++	++	**
REGRESS	++	–	++	–[a]	–[a]	–[a]
RIS	++	++	++	++	++	**
Safarova	++	++	++	++	++	*
SECURE	++	++	++	++	++	**
STARR	++	++	++	++	++	**
STOP-NIDDM	++	NR	++	++	++	NR
VITAL	+	+	++	++	++	**
WELCOME	++	++	++	++	++	**

–, not provided; +, self-report only; ++, self-report supplemented by objective criteria (e.g.: electrocardiography, echocardiography, enzymes, imaging); *, based on death certificate only; **, based on death certificate supplemented by medical record; CHD, coronary heart disease; NR, not reported; Full study names and references are provided in **Table S1**. [a]recorded but not provided. [b]fatal events only. [c]cardiovascular disease only.

Supplementary References

1 Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The Metabolic Syndrome, LDL Particle Size, and Atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2140–2147.

2 The ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687–702.

3 Kiechl S, Willeit J: In a Nutshell: Findings from the Bruneck Study. Gerontology 2019;65:9–19.

4 Lorenz MW, Kegler S von, Steinmetz H, Markus HS, Sitzer M: Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37:87–92.

5 Chien K-L, Su T-C, Jeng J-S, Hsu H-C, Chang W-T, Chen M-F, et al.: Carotid artery intima-media thickness, carotid plaque and coronary heart disease and stroke in Chinese. PLoS ONE 2008;3:e3435.

6 Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al.: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263–276.

7 Li Y, Liu J, Wang W, Zhao D: The association between within-visit blood pressure variability and carotid artery atherosclerosis in general population. PLoS ONE 2014;9:e97760.

8 Brohall G, Behre C-J, Hulthe J, Wikstrand J, Fagerberg B: Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 2006;29:363–367.

9 Allan PL, Mowbray PI, Lee AJ, Fowkes FGR: Relationship Between Carotid Intima-Media Thickness and Symptomatic and Asymptomatic Peripheral Arterial Disease. Stroke 1997;28:348–353.

10 Gabriel Sánchez R, Novella Arribas B, Alonso Arroyo M, Vega Quiroga S, López García I, Suárez Fernández C, et al.: El proyecto Epicardian: un estudio de cohortes sobre enfermedades y factores de riesgo cardiovasculares en ancianos españoles: consideraciones metodológicas y principales hallazgos demográficos. Rev Esp Salud Publica 2004;78:243–255.

11 Bonithon-Kopp C, Touboul P-J, Berr C, Leroux C, Mainard F, Courbon D, et al.: Relation of Intima-Media Thickness to Atherosclerotic Plaques in Carotid Arteries. Arterioscler Thromb Vasc Biol 1996;16:310–316.

12 Rutters F, Nijpels G, Elders P, Stehouwer CDA, van der Heijden AA, Groeneveld L, et al.: Cohort Profile: The Hoorn Studies. Int J Epidemiol 2018;47:396-396j.

13 Bickel H, Ander K-H, Brönner M, Etgen T, Gnahn H, Gotzler O, et al.: Reduction of Long-Term Care Dependence After an 8-Year Primary Care Prevention Program for Stroke and Dementia: The INVADE Trial. J Am Heart Assoc 2012;1:e000786.

14 Sempos CT, Bild DE, Manolio TA: Overview of the Jackson Heart Study: a study of cardiovascular diseases in African American men and women. Am J Med Sci 1999;317:142–146.

15 Salonen JT: Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988;20:46–50.

16 Bild DE: Multi-Ethnic Study of Atherosclerosis: Objectives and Design. Am J Epidemiol 2002;156:871–881.

17 Rundek T, Blanton SH, Bartels S, Dong C, Raval A, Demmer RT, et al.: Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke 2013;44:2101–2108.

18 Rodriguez-Macias KA, Lind L, Naessen T: Thicker carotid intima layer and thinner media layer in subjects with cardiovascular diseases. An investigation using noninvasive high-frequency ultrasound. Atherosclerosis 2006;189:393–400.

19 Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, et al.: Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med 2005;258:21–27.

20 Hofman A, Grobbee DE, Jong PT de, van den Ouweland FA: Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403–422.

21 Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, et al.: A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178–183.

22 Yuk HB, Park HW, Jung IJ, Kim WH, Kim K-H, Yang D-J, et al.: Analysis of Carotid Ultrasound Findings on Cardiovascular Events in Patients with Coronary Artery Disease during Seven-Year Follow-Up. Korean Circ J 2015;45:28–37.

23 Benedetto FA, Mallamaci F, Tripepi G, Zoccali C: Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001;12:2458–2464.

24 Izzo R, Mancusi C, Stefano G de, Albano G, Losi M-A, Trimarco V, et al.: Achievement of target SBP without attention to decrease in DBP can increase cardiovascular morbidity in treated arterial hypertension: the Campania Salute Network. J Hypertens 2019;37:1889–1897.

25 Ekart R, Hojs R, Hojs-Fabjan T, Balon BP: Predictive value of carotid intima media thickness in hemodialysis patients. Artif Organs 2005;29:615–619.

26 Stolić R, Trajković G, Jovanović A, Stolić D, Perić V, Sovtić S, et al.: Carotid ultrasonographic parameters as markers of atherogenesis and mortality rate in patients on hemodialysis. Vojnosanit Pregl 2010;67:916–922.

27 Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K, et al.: Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012;220:493–501.

28 Baldassarre D, Nyyssönen K, Rauramaa R, Faire U de, Hamsten A, Smit AJ, et al.: Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. Eur Heart J 2010;31:614–622.

29 Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, Maruyama Y, et al.: Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant 2011;26:1967–1976.

30 Landecho MF, Colina I, Huerta A, Fortuño A, Zalba G, Beloqui O: Relación entre las fases precoces de la enfermedad renal y el síndrome metabólico. Rev Esp Cardiol 2011;64:373–378.

31 Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E: Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke 2000;31:2426–2430.

32 Kitagawa K, Hougaku H, Yamagami H, Hashimoto H, Itoh T, Shimizu Y, et al.: Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis 2007;24:35–42.

33 Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri A-M, Alexopoulos E, et al.: Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:113–119.

34 Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M, Wierusz-Wysocka B: Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Res Clin Pract 2008;81:61–67.

35 Frauchiger B, Schmid HP, Roedel C, Moosmann P, Staub D: Comparison of Carotid Arterial Resistive Indices With Intima-Media Thickness as Sonographic Markers of Atherosclerosis. Stroke 2001;32:836–841.

36 Wannarong T, Parraga G, Buchanan D, Fenster A, House AA, Hackam DG, et al.: Progression of carotid plaque volume predicts cardiovascular events. Stroke 2013;44:1859–1865.

37 Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K: Visit-to-visit blood pressure variations: new independent determinants for carotid artery measures in the elderly at high risk of cardiovascular disease. J Am Soc Hypertens 2011;5:184–192.

38 The ACAPS Group: Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). Control Clin Trials 1992;13:293–314.

39 Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, et al.: Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart 2014;100:1085–1092.

40 Smilde TJ, Trip MD, Wollersheim H, van Wissen S, Kastelein JJ, Stalenhoef AF: Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia: The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study. Clin Drug Investig 2000;20:67–79.

41 Nanayakkara PWB, Teerlink T, Stehouwer CDA, Allajar D, Spijkerman A, Schalkwijk C, et al.: Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005;68:2230–2236.

42 O'Leary DH, Reuwer AQ, Nissen SE, Després J-P, Deanfield JE, Brown MW, et al.: Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011;97:1143–1150.

43 Zou Z-Y, Xu X-R, Lin X-M, Zhang H-B, Xiao X, Ouyang L, et al.: Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Br J Nutr 2014;111:474–480.

44 Bae J-H, Bassenge E, Kim K-Y, Synn Y-C, Park K-R, Schwemmer M: Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther 2004;9:185–192.

45 Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, et al.: Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2014;2:116–124.

46 Meuwese MC, Groot E de, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, et al.: ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009;301:1131–1139.

47 Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JCM, Meinders AE, et al.: Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004;27:2887–2892.

48 Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et al.: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012;23:1087–1096.

49 Asci G, Tz H, Ozkahya M, Duman S, Demirci MS, Cirit M, et al.: The impact of membrane permeability and dialysate purity on cardiovascular outcomes. J Am Soc Nephrol 2013;24:1014–1023.

50 Kastelein JJP, Sager PT, Groot E de, Veltri E: Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005;149:234–239.

51 Durga J, Bots ML, Schouten EG, Grobbee DE, Kok FJ, Verhoef P: Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults. Am J Clin Nutr 2011;93:941–949.

52 Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hâncu N, et al.: Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 2013;36:2466–2474.

53 Gresele P, Migliacci R, Arosio E, Bonizzoni E, Minuz P, Violi F: Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. J Vasc Surg 2012;56:1622-8, 1628.e1-5.

54 Held C, Sumner G, Sheridan P, McQueen M, Smith S, Dagenais G, et al.: Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vasc Med 2008;13:245–253.

55 Fulton RL, McMurdo MET, Hill A, Abboud RJ, Arnold GP, Struthers AD, et al.: Effect of Vitamin K on Vascular Health and Physical Function in Older People with Vascular Disease--A Randomised Controlled Trial. J Nutr Health Aging 2016;20:325–333.

56 Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Høieggen A, Nesbitt SD, et al.: Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. J Hypertens 2000;18:75–81.

57 Masiá M, Bernal E, Padilla S, García N, Escribano JC, Martínez E, et al.: A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. J Antimicrob Chemother 2009;64:589–598.

58 Magliano D, McNeil J, Branley P, Shiel L, Demos L, Wolfe R, et al.: The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. Eur J Cardiovasc Prev Rehabil 2006;13:341–347.

59 van Vonderen MGA, Hassink EAM, van Agtmael MA, Stehouwer CDA, Danner SA, Reiss P, et al.: Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009;199:1186–1194.

60 Cunha AR, D'El-Rei J, Medeiros F, Umbelino B, Oigman W, Touyz RM, et al.: Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women. J Hypertens 2017;35:89–97.

61 Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, et al.: Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004;27:121–126.

62 Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al.: The effect of tibolone and continuous combined conjugated equine oestrogens plus

medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746–755.

63 Skilton MR, Maple-Brown LJ, Kapellas K, Celermajer DS, Bartold M, Brown A, et al.: The effect of a periodontal intervention on cardiovascular risk markers in Indigenous Australians with periodontal disease: the PerioCardio study. BMC Public Health 2011;11:729.

64 Diercks GF, Janssen WM, van Boven AJ, Bak AA, Jong PE de, Crijns HJ, et al.: Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial PREVEND IT). Am J Cardiol 2000;86:635–638.

65 Kastelein JJP, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620–1630.

66 Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. The Lancet 2007;370:153–160.

67 Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, et al.: Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels. Circulation 1995;91:2528–2540.

68 Agewall S, Fagerberg B, Berglund G, Schmidt C, Wendelhag I, Wikstrand J: Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. J Intern Med 2001;249:305–314.

69 Safarova MS, Trukhacheva EP, Ezhov MV, Afanas'eva OI, Afanas'eva MI, Tripoten' MI, et al.: Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels. Kardiologiia 2011;51:9–16.

70 Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, et al.: Effects of Ramipril and Vitamin E on Atherosclerosis. Circulation 2001;103:919–925.

71 Lonn EM, Gerstein HC, Sheridan P, Smith S, Diaz R, Mohan V, et al.: Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 2009;53:2028–2035.

72 Temelkova-Kurktschiev T, Fischer S, Koehler C, Mennicken G, Henkel E, Hanefeld M: Intima-Media-Dicke bei Gesunden ohne Risikofaktoren für Arteriosklerose. Dtsch Med Wochenschr 2001;126:193–197.

73 Nieuwkerk PT, Nierman MC, Vissers MN, Locadia M, Greggers-Peusch P, Knape LPM, et al.: Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am J Cardiol 2012;110:666–672.

74 Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al.: Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology 2014;60:1211–1221.